WCI

RI Related News

비회원이 작성한 글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.

List Next Prev
게시글 내용
ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177
2020/04/08

ITM Isotopen Technologien Munchen AG(ITM), a biotechnology and radiopharmaceutical group of companies announced that it has expanded a long-term agreement for the supply of highly pure no-carrier-added (n.c.a.) Lutetium-177 (177Lu), which was originally concluded in 2018 between ITM AG and Endocyte, Inc., a Novartis company. Under the agreement, ITM will provide Endocyte with the supply of n.c.a 177Lu for its investigational 177Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer. Pending approval of investigational drug candidate 177Lu-PSMA-617, ITM would continue to provide its proprietary n.c.a. 177Lu during the commercial phase, supporting the scalability and security-of-supply for patients world-wide.

 

To read more please visit:

https://www.businesswire.com/news/home/20200302005435/en/ITM-expands-PSMA-617-supply-agreement-no-carrier-added-Lutetium-177

Source: Business Wire